SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Just like Uber and Netflix, Salvo is bringing on-demand care to GI
- Da Vinci Code: First Autonomous Robot Surgery Achieved in Pig Cadavers (Inside Precision Medicine)
- Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (CLP)
- Physician Services Top $1 Trillion as ASC-Linked Spending Grows (ASC News)
- AGA members push states to provide obesity care (AGA)
- Vibrant Wellness Launches Redesigned Gut Microbiome Test With Broader Microbial and Metabolic Insights (ACCESS Newswire)
- Oral Semaglutide: By Year’s End, a GLP-1 Weight-Loss Pill? (Medscape)
- Bringing Clinical Trial Enrollment to the Point of Diagnosis (Pharma’s Almanac)